Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Leslie E WagnerDepartments of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN.
Olha MelnykDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN.ORCID 0000-0001-9085-6299
Abigail TurnerDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN.
Bryce E DuffettDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN.
Charanya MuralidharanDepartments of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN.ORCID 0000-0002-4909-7056
Michelle M Martinez-IrizarryCenter for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN.ORCID 0000-0001-5995-9281
Matthew C ArvinDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN.ORCID 0000-0002-1744-2142
Kara S OrrCenter for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN.ORCID 0000-0002-1321-8581
Elisabetta ManduchiDepartment of Genetics and Institute for Diabetes, Obesity and Metabolism, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-4110-3714
Klaus H KaestnerDepartment of Genetics and Institute for Diabetes, Obesity and Metabolism, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-1228-021X
Joseph T BrozinickEli Lilly and Company, Indianapolis, IN.
Amelia K LinnemannDepartments of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN.ORCID 0000-0001-7356-4876
Funding
The Human Pancreas Analysis Program for Type 2 DiabetesU01DK123594 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Robert Babak Faryabi, KLAUS H KAESTNER · 2019 to 2026
$25.0M
Penn integrated Human Pancreas procurement and Analysis ProgramUC4DK112217 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI BETTS, MICHAEL R, FELDMAN, MICHAEL D · 2016 to 2020
$17.8M
Integrated Islet Distribution Program (U24) - 2021U24DK098085 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI Carmella Evans-Molina, Joyce Carol Niland · 2021 to 2026
$17.8M
Translation CoreP30DK097512 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI Amelia K Linnemann · 2015 to 2026
$17.4M
Supplement to Integrated Program for Human Pancreas Procurement and AnalysisUC4DK112232 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ATKINSON, MARK A., POWERS, ALVIN C · 2016 to 2020
$8.4M
Human Pancreas Analysis Program-T2DU01DK123716 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ATKINSON, MARK A., BOTTINO, RITA · 2019 to 2024
$6.6M
Autophagy/antioxidant response coupling in pancreatic beta-cell homeostasis regulationR01DK124380 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI LINNEMANN, AMELIA K · 2021 to 2025
$2.0M
Functional and molecular characterization of the human islet interferon alpha responseR03DK127766 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI LINNEMANN, AMELIA K · 2020 to 2021
$334k
Beta Cell Heterogeneity in the Interferon Alpha ResponseF31DK137567 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI WAGNER, LESLIE ELAINE · 2023 to 2024
Type 1 diabetes (T1D) is a multifactorial disease involving genetic and environmental factors, including viral infection. We investigated the impact of interferon alpha (IFN-α), a cytokine produced during the immune response to viral infection or the presence of un-edited endogenous double-stranded RNAs, on human β-cell physiology. Intravital microscopy on transplanted human islets using a β-cell-selective reactive oxygen species (ROS) biosensor (RIP1-GRX1-roGFP2), revealed a subset of human β-cells that acutely produce ROS in response to IFN-α. Comparison to Integrated Islet Distribution Program (IIDP) phenotypic data revealed that healthier donors had more ROS accumulating cells. I
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
IFN-α Induces Heterogenous ROS Production in Human β-Cells. · full record | OpenQuestion